Medical Management of Diabesity: Do We Have Realistic Targets?

@article{Pappachan2017MedicalMO,
  title={Medical Management of Diabesity: Do We Have Realistic Targets?},
  author={Joseph M Pappachan and Ananth K Viswanath},
  journal={Current Diabetes Reports},
  year={2017},
  volume={17},
  pages={1-10}
}
Purpose of ReviewThe global prevalence of “diabesity”—diabetes related to obesity—is increasing steadily over the past few decades because of the obesity epidemic. Although bariatric surgery is an effective treatment option for patients with diabesity, its limited availability, invasiveness, relatively high costs and the potential for surgical and postsurgical complications restrict its widespread use. Therefore, medical management is the only option for a majority of patients with diabesity… Expand
Diabesity and antidiabetic drugs.
TLDR
A review explores the molecular signalling cascades of antidiabetic medications in the management of diabesity and concludes that rational use of anti-diabetic medications is imperative to optimise long-term management ofdiabesity. Expand
Non-pharmacological Treatment Options in the Management of Diabetes Mellitus
TLDR
This review summarises the current evidence base for the non-pharmacological interventions in the management of diabetes and finds them useful for the effective management of even type 1 diabetes mellitus when used along with insulin therapy especially in those with obesity. Expand
Updates on obesity pharmacotherapy
TLDR
The latest updates on obesity pharmacotherapy are provided, including pharmacological management of obesity, a review of FDA‐approved weight loss medications, and obesity‐centric prescribing for mental illness, neurological disorders, and contraceptive planning. Expand
Bariatric Surgery in the Treatment of Type 2 Diabetes
TLDR
The impact of bariatric surgery on diabetes mellitus is characterized by recalling its history, examining the clinical data, exploring the putative mechanisms of action, and anticipating its future. Expand
Type 2 Diabetes Mellitus Associated with Obesity (Diabesity). The Central Role of Gut Microbiota and Its Translational Applications
TLDR
The present work aims to collect the different changes reported in gut microbiota in patients with T2DM associated with obesity and their possible role in the onset, development, and establishment of the disease. Expand
Antiobesity drugs in the management of type 2 diabetes: A shift in thinking?
TLDR
The role of antiobesity drugs in the context of medically supervised and comprehensive weight-loss interventions is described and a pragmatic therapeutic algorithm for patients with type 2 DM and obesity that incorporates the use of antiOBesity drugs early in the course of management is proposed. Expand
Diabetes, Vascular Aging and Stroke: Old Dogs, New Tricks?
Background: Stroke remains a leading cause of death and disability throughout the world. It is well established that Diabetes Mellitus (DM) is a risk factor for stroke, while other risk factorsExpand
Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force
TLDR
A consensus of expert endocrinologists representing South Asian countries including India, Pakistan, Bangladesh, Nepal, Sri Lanka, Afghanistan and the Maldives on essential recommendations related to the use of GLP-1 RAs in a real-world scenario is presented. Expand
Impact of Weight Change in Adults with Type 2 Diabetes Mellitus: A Literature Review and Critical Analysis
TLDR
Studies regarding weight change in T2DM patients demonstrated varying effects on glycemic control and a positive association with costs and resource use, where weight loss was associated with decreased costs and resources use. Expand
Multidisciplinary Team–Based Obesity Treatment in Patients With Diabetes: Current Practices and the State of the Science
TLDR
A multidisciplinary team that includes a physician with expertise in pharmacotherapy, a nurse and/or nurse practitioner, a dietitian, an exercise physiologist, and a psychologist can provide a comprehensive weight loss program combining the most effective interventions from each discipline. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 91 REFERENCES
Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians
TLDR
This guideline recommends that clinicians add oral pharmacologic therapy in patients diagnosed with type 2 diabetes when lifestyle modifications have failed to adequately improve hyperglycemia and grades the evidence and recommendations by using the American College of Physicians clinical practice guidelines grading system. Expand
Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience
TLDR
The results suggest that combination therapy with GLP-1 agonists and SGLT-2 inhibitors is a promising option for patients with diabesity. Expand
Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes.
TLDR
Among obese patients with uncontrolled type 2 diabetes, 3 years of intensive medical therapy plus bariatric surgery resulted in glycemic control in significantly more patients than did medical therapy alone. Expand
Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta‐analysis of randomized controlled trials
TLDR
Treatment with orlistat plus lifestyle intervention resulted in significantly greater weight loss and improved glycaemic control in overweight and obese patients with type 2 diabetes compared with lifestyle intervention alone. Expand
Metformin and body weight
  • A. Golay
  • Medicine
  • International Journal of Obesity
  • 2008
TLDR
The weight-neutral or weight-sparing effects of metformin constitute a therapeutic advantage in diabetes management where other first-line oral antidiabetic treatments often promote clinically significant weight gain. Expand
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
TLDR
The proportion reaching an A1c of <7% was generally similar across therapies (59% for sulfonylurea, 59% for After Metformin, What Comes Next? Empagliflozin). Expand
Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials
TLDR
The landmark ORIGIN trial provides many lessons relating to the concept and application of early insulin therapy for the prevention and safe and effective induction and maintenance of glycemic control in type 2 diabetes. Expand
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
TLDR
3.0 mg of liraglutide, as an adjunct to diet and exercise, was associated with reduced body weight and improved metabolic control in patients with type 2 diabetes and prediabetes. Expand
A Multicenter Observational Study of Incretin-based Drugs and Heart Failure.
TLDR
In this analysis of data from large cohorts of patients with diabetes, incretin-based drugs were not associated with an increased risk of hospitalization for heart failure, as compared with commonly used combinations of oral antidiabetic drugs. Expand
Comparative efficacy and safety of OADs in management of GDM: network meta-analysis of randomized controlled trials.
TLDR
Both metformin and glyburide are suitable for use in the management of gestational diabetes because of good glycemic control, however, glyBuride treatment is associated with increased risk of neonatal hypoglycemia, high maternal weight gain, high neonatal birth weight, and macrosomia. Expand
...
1
2
3
4
5
...